Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vecti-BIL: Panitumumab + GEMOX in Biliary Tract Cancer
NCT01389414Phase 2Completed
- Start
- May 2010
- Primary completion
- Sep 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in biliary tract cancer (BTC) (2 arms). Primary endpoint: Progression-Free Survival. Started May 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT01389414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01389414.